IF 2.1 3区医学

Urology Pub Date : 2025-01-10 DOI: 10.1016/j.urology.2024.12.036

Taciana Leonel Nunes Tiraboschi, Eduardo P Miranda, Monique Tonani Novaes, Caroline Santos Silva, Jean Carlos Zambrano Contreras, Jarbas de Sá Roriz Filho, Ernesto Reggio, Caio Vinícius Suartz, Cristiano Mendes Gomes, José de Bessa

{"title":"Rethinking Low Testosterone in Older Men: Association With Obesity Rather Than Aging.","authors":"Taciana Leonel Nunes Tiraboschi, Eduardo P Miranda, Monique Tonani Novaes, Caroline Santos Silva, Jean Carlos Zambrano Contreras, Jarbas de Sá Roriz Filho, Ernesto Reggio, Caio Vinícius Suartz, Cristiano Mendes Gomes, José de Bessa","doi":"10.1016/j.urology.2024.12.036","DOIUrl":"10.1016/j.urology.2024.12.036","url":null,"abstract":"Objective: The decline in testosterone levels among older men remains a subject of debate. While some cross-sectional and longitudinal studies have reported a decrease in testosterone with advancing age, others have not observed this trend. In this study, we aimed to evaluate testosterone levels and identify predictors of low testosterone in an age-stratified cohort of men.Methods: From January 2016 to June 2022, a cohort of men receiving routine care at a primary care center was prospectively analyzed. Participants were stratified into age groups: 45-64 years (middle-aged), 65-74 years (young-old), 75-84 years (middle-old), and ≥85 years (oldest-old). Comprehensive clinical and laboratory assessments were conducted, including waist circumference, glucose levels, triglycerides, HDL cholesterol, and total testosterone. Low testosterone was defined as levels below 300ng/dL. Metabolic syndrome was diagnosed in accordance with established diagnostic criteria.Results: The study included 3.489 subjects across age groups. Median testosterone levels were similar across all age groups. The prevalence of low testosterone was around 20% in all groups and did not significantly vary with age. Obesity, as indicated by increased waist circumference (WC) >102 cm, was strongly associated with low testosterone. The prevalence of low testosterone increased from 8% in those with WC≤93cm to 44% in those with WC≥110cm.Conclusion: This study highlights the significant association between low testosterone levels and obesity, reinforcing the importance of addressing comorbidities in testosterone decline.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Comment on "Long Term Fate of Testis Prosthesis After Metoidioplasty and Phalloplasty". 编辑评论“metoidiom成形术和阴茎成形术后睾丸假体的长期命运”。

IF 2.1 3区医学

Urology Pub Date : 2025-01-09 DOI: 10.1016/j.urology.2025.01.013

Joseph J Pariser

引用次数: 0

Surgical Outcomes of the ZSI475 FtM Inflatable Erectile Prosthesis Implantation After Phalloplasty. zsi475ftm充气勃起假体阴茎成形术后的手术效果。

IF 2.1 3区医学

Urology Pub Date : 2025-01-09 DOI: 10.1016/j.urology.2025.01.002

Salomé Marchand, Nicolas Morel-Journel, Damien Carnicelli, Fabien Boucher, Alain Ruffion, Paul Neuville

{"title":"Surgical Outcomes of the ZSI475 FtM Inflatable Erectile Prosthesis Implantation After Phalloplasty.","authors":"Salomé Marchand, Nicolas Morel-Journel, Damien Carnicelli, Fabien Boucher, Alain Ruffion, Paul Neuville","doi":"10.1016/j.urology.2025.01.002","DOIUrl":"10.1016/j.urology.2025.01.002","url":null,"abstract":"Objective: To report the surgical outcomes and complications experienced after implantation of the ZSI475 FtM prosthesis after phalloplasty.Methods: All consecutive patients who underwent ZSI475FtM prosthesis implantation in their neophallus between January 2016 and March 2024 in our center were included. There was no exclusion criterion. We considered the occurrence of a complication according to the date of first appearance in the medical record.Results: A total of 89 patients, accounting for 130 implantation surgeries, were included. Among the 130 implantations, 69 (53.1%) led to a complication; the most frequent was mechanical dysfunction (52/130, 40.0%), followed by infection (8/130, 6.2%), malposition (7/130, 5.4%), and erosion (2/130, 1.5%). All cases of infection and erosion were treated by prosthesis removal. Overall, these complications led to 60 revision surgeries for replacement (41/60, 68.3%), removal (17/60, 28.3%), and refixation (2/60, 3.3%). The median follow-up was 3.9years [IQR, 2.3-5.5], and the median time to complication was 1.6years [IQR, 0.4-2.4]. The median survival time of the prosthesis was 5.4years [IQR, 4.6-5.9] and the 4-year probability of survival was 74.0% (95%CI [65.6-83.4]).Conclusion: The ZSI475 FtM implant shows a survival probability similar to the rates reported in the literature. Future improvements are needed to increase its robustness and survival. The next step toward a better understanding of the associated complications will involve multicenter data collection of the surgical outcomes.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes. 吉西他滨膀胱内联合多西他赛和膀胱内卡介苗治疗非肌肉侵袭性原发性膀胱癌的比较：肿瘤预后的系统回顾和荟萃分析。

IF 2.1 3区医学

Urology Pub Date : 2025-01-09 DOI: 10.1016/j.urology.2025.01.004

Rachana Tripathy, Lalit Kumar, Sakshi Agarwal, Anuja Thakur, Mahesh Khairnar, Sameer Trivedi, S N Sankhwar

{"title":"A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes.","authors":"Rachana Tripathy, Lalit Kumar, Sakshi Agarwal, Anuja Thakur, Mahesh Khairnar, Sameer Trivedi, S N Sankhwar","doi":"10.1016/j.urology.2025.01.004","DOIUrl":"https://doi.org/10.1016/j.urology.2025.01.004","url":null,"abstract":"Objective: To evaluate the efficacy, recurrence rates, and safety profile of intravesical gemcitabine plus docetaxel versus standard Bacillus Calmette-Guérin (BCG) therapy for treating naïve non-muscle-invasive bladder cancer (NMIBC), focusing on reducing recurrence and progression concerns associated with transurethral resection (TURBT).Methods: Relevant articles were identified and appraised through a structured assessment of the literature. Databases searched included PubMed, Medline, Scopus, and Science Direct.Results: The meta-analysis incorporated a quantitative assessment of 3 original articles. The meta-analysis studies evaluated parameters, including the recurrence rate and safety profile. The I2 statistics indicated no heterogeneity in recurrence rates between the gemcitabine plus docetaxel (experimental) group and the BCG (control) treatment group. According to the results, the cumulative Odds Ratio for the recurrence rate was 0.72 (95% CI: 0.36-1.47), favoring a slightly lower recurrence rate clinically in the experimental group. The overall effect test yielded a Z-value of 0.89 with a P-value of 0.37, indicating no statistically significant difference in outcome odds between the experimental and control groups.Conclusions: The meta-analysis showed a slightly lower clinical recurrence rate in the intravesical gemcitabine plus docetaxel group than in the intravesical BCG treatment group. The intravesical gemcitabine plus docetaxel group experienced fewer severe side effects. There are limited number of studies available at present. This meta-analysis suggests need of further randomized studies to establish role of intravesical gemcitabine plus docetaxel in NMIBC.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor on "Martius Labial Fat Pad Use in the Treatment of Complications Associated With Prior Surgery for Urinary Incontinence or Pelvic Organ Prolapse". 致编辑的信“Martius唇脂垫用于治疗尿失禁或盆腔器官脱垂手术相关并发症”。

IF 2.1 3区医学

Urology Pub Date : 2025-01-09 DOI: 10.1016/j.urology.2025.01.015

Kemal Demirhan

引用次数: 0

Reply to Editorial Comment on "Student Urology Conference Increases Participant Knowledge of Urology Match and Confidence in Research". 回复关于“学生泌尿学会议增加参与者泌尿学匹配知识和研究信心”的社论评论。

IF 2.1 3区医学

Urology Pub Date : 2025-01-09 DOI: 10.1016/j.urology.2025.01.008

Isaac E Kim, Gyan Pareek

引用次数: 0

Letter to the Editor on: "Extended Treatment-dose Antibiotic Therapy Versus Low-dose Prophylaxis for the Management of Recurrent Uncomplicated Urinary Tract Infections in Peri- and Postmenopausal Women". 致编辑的信：“延长治疗剂量抗生素治疗与低剂量预防治疗对围绝经期和绝经后妇女复发性无并发症尿路感染的管理”。